Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Company Overview

Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to address both cancer cells and the tumor microenvironment, which can suppress immune responses and limit the effectiveness of existing treatments.

Bicara’s lead product candidate is ficerafusp alfa, also known as BCA101. It is an investigational bifunctional fusion protein designed to target the epidermal growth factor receptor (EGFR) on tumor cells while blocking transforming growth factor beta (TGF-β), a signaling pathway associated with tumor growth and immune suppression. The company is evaluating ficerafusp alfa in clinical studies, including combination treatment with immune checkpoint inhibitors for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Based in Cambridge, Massachusetts, Bicara is developing its pipeline for cancers in which EGFR signaling and the tumor microenvironment may play important roles. Its programs remain investigational and have not been approved for commercial use by regulatory authorities.

Key Stats

• Today's Range: $17.16 to $17.68
• 50-Day Range: $16.42 to $28.06
• 52-Week Range: $13.70 to $30.99
• Volume: 1.07 million shs
• Average Volume: 620,039 shs
• Market Capitalization: $1.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.64
• Consensus Rating: Moderate Buy

Bicara Therapeutics Stock Analysis - MarketRank™

Bicara Therapeutics scored higher than 51% of companies evaluated by MarketBeat, and ranked 543rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Bicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 strong buy ratings, 9 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Bicara Therapeutics has a consensus price target of $32.64, representing about 88.5% upside from its current price of $17.31.

Amount of Analyst Coverage

Bicara Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Bicara Therapeutics are expected to decrease in the coming year, from ($3.49) to ($3.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bicara Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bicara Therapeutics is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bicara Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.75% of the float of Bicara Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Bicara Therapeutics has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.

Change versus previous month

Short interest in Bicara Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bicara Therapeutics does not currently pay a dividend.

Dividend Growth

Bicara Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.71

News Sentiment

Bicara Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Bicara Therapeutics this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for BCAX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,554,800.00 in company stock.

Percentage Held by Insiders

13.80% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Bicara Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCAX
• Previous Symbol: NASDAQ:BCAX
• CIK: 2023658
• Web: www.bicara.com
• Phone: (617) 468-4219
• Fax: N/A
• Employees: 103
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Bicara Therapeutics: $32.64
• High Price Target: $42.00
• Low Price Target: $20.00
• Potential Upside/Downside: +88.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$137.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.49%
• Return on Assets: -38.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.59
• Quick Ratio: 11.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.33 per share
• Price / Book: 2.37

Miscellaneous

• Outstanding Shares: 66,170,000
• Free Float: 57,041,000
• Market Cap: $1.15 billion
• Optionable: N/A
• Beta: -0.70